Astrana Health Financials
Astrana Health (ASTH) reported $3.2B in revenue for fiscal year 2025, up 56.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Astrana’s recent growth looks like externally funded scale expansion, with margin compression absorbing much of the added volume.
From FY2023 to FY2025, gross margin fell from15.5% to10.7% even as revenue more than doubled, which implies newer volume arrived with thinner economics rather than better scale benefits. Yet FY2025 operating cash flow of$114.6M far exceeded net income of$24.0M , so the pressure is showing up more in reported earnings than in cash generation.
Goodwill reached
FY2025 free cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Astrana Health's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Astrana Health has an operating margin of 2.5%, meaning the company retains $2 of operating profit per $100 of revenue. This results in a moderate score of 50/100, indicating healthy but not exceptional operating efficiency. This is down from 4.4% the prior year.
Astrana Health's revenue surged 56.4% year-over-year to $3.2B, reflecting rapid business expansion. This strong growth earns a score of 95/100.
Astrana Health has elevated debt relative to equity (D/E of 1.27), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 12/100, reflecting increased financial risk.
Astrana Health's current ratio of 1.40 indicates adequate short-term liquidity, earning a score of 37/100. The company can meet its near-term obligations, though with limited headroom.
Astrana Health has a free cash flow margin of 3.3%, earning a moderate score of 39/100. The company generates positive cash flow after capital investments, but with room for improvement.
Astrana Health's ROE of 3.1% shows moderate profitability relative to equity, earning a score of 63/100. This is down from 7.0% the prior year.
Astrana Health scores 2.55, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Astrana Health passes 3 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Astrana Health generates $4.77 in operating cash flow ($114.6M OCF vs $24.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Astrana Health earns $1.57 in operating income for every $1 of interest expense ($78.5M vs $49.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Astrana Health generated $3.2B in revenue in fiscal year 2025. This represents an increase of 56.4% from the prior year.
Astrana Health's EBITDA was $124.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.0% from the prior year.
Astrana Health reported $24.0M in net income in fiscal year 2025. This represents a decrease of 52.0% from the prior year.
Astrana Health earned $0.46 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 48.9% from the prior year.
Cash & Balance Sheet
Astrana Health generated $104.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 136.6% from the prior year.
Astrana Health held $429.5M in cash against $990.9M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Astrana Health's gross margin was 10.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 2.6 percentage points from the prior year.
Astrana Health's operating margin was 2.5% in fiscal year 2025, reflecting core business profitability. This is down 1.9 percentage points from the prior year.
Astrana Health's net profit margin was 0.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 1.7 percentage points from the prior year.
Astrana Health's ROE was 3.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 3.9 percentage points from the prior year.
Capital Allocation
Astrana Health spent $25.6M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 2744.4% from the prior year.
Astrana Health invested $10.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 25.8% from the prior year.
Not reported for fiscal year 2025.
ASTH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8B | $3.2B+56.4% | $2.0B+46.7% | $1.4B+21.2% | $1.1B+47.8% | $773.9M+12.6% | $687.2M+22.6% | $560.6M+7.8% | $519.9M+45.9% | $356.4M | $57.4M+30.4% | $44.0M+33.5% | $33.0M+214.7% | $10.5M+34.8% | $7.8M+52.2% | $5.1M |
| Cost of Revenue | $3.4B | $2.8B+61.1% | $1.8B+50.5% | $1.2B+24.0% | $944.7M+58.5% | $596.1M+10.6% | $539.2M+15.3% | $467.8M+29.5% | $361.1M+32.1% | $273.5M | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $402.0M | $341.5M+25.8% | $271.4M+26.3% | $215.0M+7.8% | $199.5M+12.2% | $177.8M+20.1% | $148.0M+59.4% | $92.8M-41.5% | $158.8M+91.5% | $82.9M | N/A | N/A | N/A | $1.4M-3.6% | $1.5M+49.2% | $978K |
| SG&A Expenses | $238.5M | $217.3M+41.0% | $154.1M+36.9% | $112.6M+45.0% | $77.7M+25.1% | $62.1M+26.4% | $49.1M+18.4% | $41.5M-4.3% | $43.4M+65.2% | $26.2M | $21.0M+24.0% | $17.0M+50.3% | $11.3M+113.4% | $5.3M+50.3% | $3.5M+155.1% | $1.4M |
| Operating Income | $100.5M | $78.5M-12.1% | $89.3M+5.6% | $84.6M-18.8% | $104.3M+6.2% | $98.2M+22.0% | $80.5M+148.3% | $32.4M-63.3% | $88.4M+151.6% | $35.1M | $11.7M+260.9% | -$7.3M-946.5% | -$694K+82.2% | -$3.9M-88.1% | -$2.1M-402.9% | -$413K |
| Interest Expense | $67.3M | $49.9M+50.9% | $33.1M+105.5% | $16.1M+103.3% | $7.9M+46.8% | $5.4M-43.2% | $9.5M+100.7% | $4.7M+743.7% | $561K+604.0% | $80K | $62K-88.6% | $542K-59.1% | $1.3M+95.3% | $679K-27.0% | $930K+205.9% | $304K |
| Income Tax | $20.9M | $15.5M-49.7% | $30.9M-3.4% | $32.0M-21.7% | $40.9M+29.0% | $31.7M-43.8% | $56.3M+589.9% | $8.2M-63.5% | $22.4M+475.3% | $3.9M | $8.8M+12511.0% | -$71K-143.4% | $164K+739.4% | $20K+306.5% | $5K-17.5% | $6K |
| Net Income | $42.1M | $24.0M-52.0% | $50.0M-13.8% | $58.0M+26.1% | $46.0M0.0% | $46.0M+22.1% | $37.7M+167.0% | $14.1M+30.3% | $10.8M-58.0% | $25.8M | $11.5M+222.6% | -$9.3M-418.4% | -$1.8M+64.1% | -$5.0M+43.6% | -$8.9M-1136.2% | -$720K |
| EPS (Diluted) | — | $0.46-48.9% | $0.90 | $1.29 | $0.99 | $1.52+50.5% | $1.01+159.0% | $0.39+34.5% | $0.29-67.8% | $0.90 | $0.41 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: R&D Expenses.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ASTH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.2B+63.8% | $1.4B+45.2% | $933.4M-3.4% | $966.2M+11.4% | $867.4M+6.1% | $817.5M+12.2% | $728.7M+42.0% | $513.0M+4.6% | $490.6M | $20.6M+5.5% | $19.6M+30.5% | $15.0M+278.7% | $4.0M+22.9% | $3.2M+136.3% | $1.4M |
| Current Assets | $863.3M+35.2% | $638.5M+38.4% | $461.5M+7.8% | $428.1M+5.9% | $404.5M+19.5% | $338.6M+2.9% | $329.1M+90.4% | $172.9M+19.9% | $144.2M | $14.9M+10.1% | $13.6M+37.6% | $9.9M+216.4% | $3.1M+8.4% | $2.9M+129.9% | $1.2M |
| Cash & Equivalents | $429.5M+48.9% | $288.5M-1.8% | $293.8M+2.0% | $288.0M+23.6% | $233.1M+20.5% | $193.5M+87.5% | $103.2M-3.5% | $106.9M+7.2% | $99.7M | N/A | $9.3M+84.9% | $5.0M+232.5% | $1.5M+28.2% | $1.2M+615.9% | $164K |
| Accounts Receivable | $374.5M+35.7% | $276.0M | N/A | $49.6M+367.9% | $10.6M+50.3% | $7.1M-35.9% | $11.0M+42.3% | $7.7M+1.7% | $7.6M | $5.5M+62.3% | $3.4M-10.7% | $3.8M+151.8% | $1.5M-4.6% | $1.6M+59.2% | $994K |
| Goodwill | $865.3M+106.4% | $419.3M+50.4% | $278.8M+3.6% | $269.1M+9.2% | $246.4M+6.0% | $232.4M-2.5% | $238.5M+28.4% | $185.8M-2.1% | $189.8M | $1.6M0.0% | $1.6M-25.2% | $2.2M+338.4% | $495K+1390.1% | $33K+3.8% | $32K |
| Total Liabilities | $1.7B+97.5% | $840.7M+60.9% | $522.6M+28.2% | $407.7M+14.3% | $356.7M-4.2% | $372.3M-30.7% | $537.2M+61.6% | $332.5M+0.5% | $330.7M | $20.4M-2.2% | $20.8M+30.3% | $16.0M+143.0% | $6.6M+82.0% | $3.6M+102.5% | $1.8M |
| Current Liabilities | $615.3M+68.3% | $365.6M+67.2% | $218.7M+47.1% | $148.6M+29.5% | $114.7M-0.2% | $115.0M+9.1% | $105.4M+46.4% | $72.0M-34.3% | $109.6M | $14.5M+95.7% | $7.4M+24.6% | $6.0M+31.1% | $4.6M+167.0% | $1.7M+12.5% | $1.5M |
| Long-Term Debt | $990.9M+133.0% | $425.3M+64.2% | $258.9M+27.3% | $203.4M+11.2% | $182.9M-20.5% | $230.2M-0.8% | $232.2M | $0 | N/A | N/A | N/A | $10.7M | N/A | N/A | N/A |
| Total Equity | $779.3M+9.3% | $712.7M+16.0% | $614.2M+13.2% | $542.6M+21.1% | $448.2M+35.5% | $330.8M+72.7% | $191.5M+6.1% | $180.5M+12.9% | $159.9M | -$354K+72.1% | -$1.3M+54.9% | -$2.8M-7.6% | -$2.6M-638.0% | -$355K+46.2% | -$659K |
| Retained Earnings | $308.4M+7.7% | $286.3M+17.7% | $243.1M+33.3% | $182.4M+32.9% | $137.2M+96.7% | $69.8M+118.7% | $31.9M+79.4% | $17.8M+925.5% | $1.7M | -$37.7M-31.3% | -$28.7M-48.3% | -$19.3M-15.3% | -$16.8M-52.2% | -$11.0M-420.5% | -$2.1M |
Not reported in any period shown, so not listed: Inventory.
ASTH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $107.9M | $114.6M+119.5% | $52.2M-23.5% | $68.2M-16.9% | $82.1M+16.8% | $70.3M+52.4% | $46.2M+237.6% | $13.7M-46.4% | $25.5M-50.8% | $51.8M | $21.9M+1291.5% | -$1.8M-576.4% | -$272K+81.6% | -$1.5M-2650.6% | $58K+115.0% | -$385K |
| Capital Expenditures | $13.5M | $10.1M+25.8% | $8.0M-71.8% | $28.5M+24.4% | $22.9M+19.3% | $19.2M+1551.5% | $1.2M+11.7% | $1.0M-10.9% | $1.2M-43.9% | $2.1M | $3.3M+1161.4% | $262K+488.9% | $45K+94.1% | $23K-49.9% | $46K+535.7% | $7K |
| Free Cash Flow | $94.4M | $104.5M+136.6% | $44.2M+11.3% | $39.7M-32.9% | $59.2M+15.8% | $51.1M+13.6% | $45.0M+256.3% | $12.6M-48.1% | $24.3M-51.1% | $49.7M | $18.6M+985.6% | -$2.1M-564.1% | -$316K+78.9% | -$1.5M-12447.9% | $12K+103.1% | -$393K |
| Investing Cash Flow | -$544.6M | -$539.0M-180.2% | -$192.4M-193.6% | -$65.5M-821.2% | -$7.1M-143.0% | $16.5M-82.7% | $95.5M+152.9% | -$180.6M-617.3% | -$25.2M-194.3% | $26.7M | -$9.0M | N/A | N/A | -$273K-761.4% | -$32K-120.2% | $157K |
| Financing Cash Flow | $502.1M | $569.3M+321.3% | $135.1M+3850.5% | $3.4M+117.0% | -$20.1M+57.9% | -$47.7M+7.6% | -$51.7M-131.7% | $163.3M+1561.4% | -$11.2M+25.4% | -$15.0M | -$17.1M | N/A | N/A | $2.0M+105.4% | $986K+23085.9% | -$4K |
| Dividends Paid | $1.9M | $7.9M+95.4% | $4.0M-93.5% | $62.1M+342.4% | $14.0M-54.9% | $31.1M-39.4% | $51.3M-16.8% | $61.7M+247.5% | $17.8M+70.0% | $10.4M | $26.7M | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $17.8M | $25.6M+2744.4% | $900K-91.2% | $10.2M+10.2% | $9.3M+61.2% | $5.7M+968.7% | $537K-92.9% | $7.6M+50.0% | $5.0M+58.9% | $3.2M | $518K | N/A | $500 | $0 | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ASTH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 10.7%-2.6pp | 13.3%-2.2pp | 15.5%-1.9pp | 17.4%-5.5pp | 23.0%+1.4pp | 21.5%+5.0pp | 16.6%-14.0pp | 30.5%+7.3pp | 23.3% | N/A | N/A | N/A | 13.4%-5.3pp | 18.8%-0.4pp | 19.1% |
| Operating Margin | 2.5%-1.9pp | 4.4%-1.7pp | 6.1%-3.0pp | 9.1%-3.6pp | 12.7%+1.0pp | 11.7%+5.9pp | 5.8%-11.2pp | 17.0%+7.2pp | 9.9% | 20.3%+36.9pp | -16.5%-14.4pp | -2.1%+35.2pp | -37.3%-10.6pp | -26.7%-18.6pp | -8.1% |
| Net Margin | 0.8%-1.7pp | 2.5%-1.7pp | 4.2%+0.2pp | 4.0%-1.9pp | 5.9%+0.5pp | 5.5%+3.0pp | 2.5%+0.4pp | 2.1%-5.2pp | 7.2% | 19.9%+41.1pp | -21.2%-15.8pp | -5.5%+42.4pp | -47.9% | -114.5% | -14.1% |
| Return on Equity | 3.1%-3.9pp | 7.0%-2.4pp | 9.4%+1.0pp | 8.5%-1.8pp | 10.3%-1.1pp | 11.4%+4.0pp | 7.4%+1.4pp | 6.0%-10.1pp | 16.1% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 1.1%-2.6pp | 3.7%-2.5pp | 6.2%+1.4pp | 4.8%-0.5pp | 5.3%+0.7pp | 4.6%+2.7pp | 1.9%-0.2pp | 2.1%-3.1pp | 5.3% | 55.5%+103.2pp | -47.8%-35.7pp | -12.0%+114.8pp | -126.8%+149.5pp | -276.3%-223.5pp | -52.8% |
| Current Ratio | 1.40-0.3x | 1.75-0.4x | 2.11-0.8x | 2.88-0.6x | 3.53+0.6x | 2.94-0.2x | 3.12+0.7x | 2.40+1.1x | 1.32 | 1.03-0.8x | 1.82+0.2x | 1.65+1.0x | 0.68-1.0x | 1.68+0.9x | 0.82 |
| Debt-to-Equity | 1.27+0.7x | 0.60+0.2x | 0.420.0x | 0.370.0x | 0.41-0.3x | 0.70-0.5x | 1.21+1.2x | 0.00-2.1x | 2.07 | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | 3.3%+1.1pp | 2.2%-0.7pp | 2.9%-2.3pp | 5.2%-1.4pp | 6.6%+0.1pp | 6.6%+4.3pp | 2.3%-2.4pp | 4.7%-9.3pp | 14.0% | 32.4%+37.2pp | -4.8%-3.8pp | -1.0%+13.4pp | -14.3%-14.5pp | 0.2%+7.8pp | -7.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Where Astrana Health Ranks
Frequently Asked Questions
What is Astrana Health's annual revenue?
Astrana Health (ASTH) reported $3.2B in total revenue for fiscal year 2025. This represents a 56.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Astrana Health's revenue growing?
Astrana Health (ASTH) revenue grew by 56.4% year-over-year, from $2.0B to $3.2B in fiscal year 2025.
Is Astrana Health profitable?
Yes, Astrana Health (ASTH) reported a net income of $24.0M in fiscal year 2025, with a net profit margin of 0.8%.
What is Astrana Health's EBITDA?
Astrana Health (ASTH) had EBITDA of $124.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Astrana Health have?
As of fiscal year 2025, Astrana Health (ASTH) had $429.5M in cash and equivalents against $990.9M in long-term debt.
What is Astrana Health's gross margin?
Astrana Health (ASTH) had a gross margin of 10.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Astrana Health's operating margin?
Astrana Health (ASTH) had an operating margin of 2.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Astrana Health's net profit margin?
Astrana Health (ASTH) had a net profit margin of 0.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Astrana Health's return on equity (ROE)?
Astrana Health (ASTH) has a return on equity of 3.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Astrana Health's free cash flow?
Astrana Health (ASTH) generated $104.5M in free cash flow during fiscal year 2025. This represents a 136.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Astrana Health's operating cash flow?
Astrana Health (ASTH) generated $114.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Astrana Health's total assets?
Astrana Health (ASTH) had $2.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Astrana Health's capital expenditures?
Astrana Health (ASTH) invested $10.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Astrana Health's current ratio?
Astrana Health (ASTH) had a current ratio of 1.40 as of fiscal year 2025, which is considered adequate.
What is Astrana Health's debt-to-equity ratio?
Astrana Health (ASTH) had a debt-to-equity ratio of 1.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Astrana Health's return on assets (ROA)?
Astrana Health (ASTH) had a return on assets of 1.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Astrana Health's Altman Z-Score?
Astrana Health (ASTH) has an Altman Z-Score of 2.55, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Astrana Health's Piotroski F-Score?
Astrana Health (ASTH) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Astrana Health's earnings high quality?
Astrana Health (ASTH) has an earnings quality ratio of 4.77x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Astrana Health cover its interest payments?
Astrana Health (ASTH) has an interest coverage ratio of 1.57x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Astrana Health?
Astrana Health (ASTH) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.